Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options

Benzinga
Abrir em Benzinga